PMR: reduction of minimum of 30% in target measurable tumor 18F-FDG SUL peak. Absolute drop in SUL must be at least 0.8 SUL units, as well. Measurement is commonly in same lesion as baseline but can be another lesion if that lesion was previously present and is the most active lesion after treatment. ROI does not have to be in precisely same area as baseline scan, though typically it is. No increase, .30% in SUL or size of target or nontarget lesions (i.e., no PD by RECIST or IWC) (if PD anatomically, must verify with follow-up). Reduction in extent of tumor 18F-FDG uptake is not requirement for PMR. Percentage decline in SUL should be recorded, as well as (ideally) time in weeks after treatment was begun (i.e., PMR 240, 3). No new lesions.